top of page
LATEST NEWS
FDA Proposes One Approval for Many Mutations in Personalized Gene Editing
A new FDA draft guidance would let one license cover a personalized gene editor and its patient-specific versions. New mutations could be added with lab data instead of new clinical trials, a path built for cases like KJ Muldoon's.
3 days ago4 min read


Estuary Launches With $103 Million to Bring Gene Therapy to Polycystic Kidney Disease
Estuary Biotherapeutics launched with $103 million to develop one-time, kidney-directed AAV gene therapies for ADPKD, the most common inherited kidney disease. Here is how restoring polycystin proteins could stop, or even reverse, kidney cysts.
Oct 224 min read


Should Gene Therapy Be Used for Common Diseases? Two Cardiologists Propose Five Questions
One-time genetic treatments are moving from rare diseases to common ones like high cholesterol. In JAMA Internal Medicine, two University of Michigan cardiologists explain why permanence, rare side effects and cost call for a new framework.
Oct 224 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Light-Induced Gene Therapy Using Nanoparticles Targets and Destroys Cancer Cells' Mitochondria
A groundbreaking new approach in cancer treatment has emerged, utilizing light to disable the mitochondria, the energy-producing organelles inside cancer cells. Researchers at Ohio State University have developed a targeted gene therapy using viral vectors, specifically engineered adeno-associated viruses (AAVs), that deliver genes designed to disrupt mitochondrial function directly to cancer cells. This therapy uses light to activate these genes, leading to the collapse of t
Feb 8, 2025


Gene Therapy Restores Enzyme Levels to Treat Hypophosphatasia - A More Permanent Treatment
Hypophosphatasia (HPP), or "soft bone disease" is a rare genetic disorder that impacts bone and tooth development, leading to weak bones and other health complications. For years, enzyme replacement therapy has been the only effective treatment for HPP. This therapy involves injecting asfotase alfa, an enzyme that replaces the missing one in patients’ bodies. However, these injections must be given three to six times a week, which can be challenging for many patients. While t
Feb 4, 2025


Gene and Cell Therapy Clinical Trials to Notice in 2025
Several clinical trials in 2025 are pushing the boundaries of gene and cell therapy, aiming to address a range of complex diseases. Below is an overview of five major trials that could provide significant breakthroughs for patients suffering from genetic disorders, cancer, and autoimmune conditions. Intellia Therapeutics’ Gene-Editing Therapy for Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disorder that causes episodes of severe swelling, often in the
Jan 31, 2025


Vertex’s Stem Cell Therapy: A Bold Leap Toward a Type I Diabetes Cure
Vertex Pharmaceuticals has announced a pivotal milestone for its VX-880 therapy, a stem-cell-derived islet cell treatment to restore insulin production in people with type 1 diabetes (T1D). The treatment, which previously underwent a Phase 1/2 clinical trial, is now entering a Phase 1/2/3 trial, making it the first scalable T1D cure to reach this advanced stage. This combined trial streamlines the research process, integrating safety, efficacy, and confirmatory studies into a
Jan 13, 2025


Regenerating Hearts: How Stem Cell Therapy Could Transform the Treatment of Congenital Heart Diseases
Heart disease is a leading cause of death worldwide, affecting millions at every stage of life, including infants born with congenital heart defects. These conditions often result in a weakened heart, leading to symptoms such as chest pain, breathlessness, and swelling. If untreated, they can be fatal. While surgeries can offer temporary relief, many patients eventually face heart failure. They may require a heart transplant—a challenging solution due to the scarcity of donor
Nov 30, 2024


FDA Approves Stem Cell Therapy, Regenecyte, Shown to Help Chemotherapy Patients Recover Blood Count
The FDA has approved Regenecyte, an innovative therapy made from umbilical cord blood stem cells, to help rebuild blood and immune systems in patients with blood disorders or those recovering from intense treatments like chemotherapy. This breakthrough offers a promising option for patients needing healthy blood cell regeneration. Regenecyte uses stem cells collected from umbilical cords, which are highly adaptable and can grow into essential blood and immune cells. The treat
Nov 29, 2024


Revolutionary Gene Therapy Targeting Galectin 1 Shows Promise in Reducing Liver Cancer Incidence in Animal Models
New Approach for Liver Cancer Treatment and Possible Prevention: Gene Therapy Targets Biomarker for Hepatocellular Carcinoma (HCC) Researchers at the UC Davis Comprehensive Cancer Center have unveiled a promising gene therapy approach that significantly reduces the incidence of hepatocellular carcinoma (HCC) in animal models, specifically mice. This innovative research targets a specific protein known as galectin 1 (Gal1), which has long been established as a critical biomark
Feb 2, 2024
bottom of page


